Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Fluidigm; Smiths Detection; Oxford Gene Technology; Promega

NEW YORK (GenomeWeb News) – Fluidigm said this week that a Japanese university is using the firm's BioMark System for Genetic Analysis in its research on mouse hematopoietic single stem cells. The system is being used in the lab of Toshio Suda at Keio University's 21st Century Center of Excellence Program in the Graduate School of Medicine.

Smiths Detection said that it is launching a partnership and licensing program for its LATE PCR DNA amplification and analysis technique. The London-based firm said that it is able to offer in collaboration with PHRI Properties the LATE PCR and Molecular Beacons through a single license. PHRI is a nonprofit company that is wholly owned by the University of Medicine and Dentistry of New Jersey.

Oxford Gene Technology this week said that the Center for Human genetics at Katholieke Universiteit Leuven, Belgium, has begun assessing the firm's CytoSure assays for use in prenatal diagnostics research. The study will last 12 months and will sue the arrays alongside existing screening techniques, said OGT.

Promega has opened its EuroLab facility in Charbonnaires, near Lyon, France, the firm said this week. The new facility will serve as a center of excellence and train Promega scientific support personal. It also will be involved in developing new applications that address emerging scientific needs in Europe.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.